StreetAlpha.app
Home › Stocks › RNXT

RenovoRx, Inc. (RNXT)

$0.94
▼ −10.29%
LAST CLOSE · NOV 20

RenovoRx develops RenovoCath, a drug delivery device, and other drug and device combination products for healthcare providers. It last closed at $0.94 on Nov 20, down 10.29% on the day. The next earnings report for RNXT is expected around Mon, Mar 29, 2027, after the close. For the quarter ended Sep 2026, RNXT reported EPS of -$0.08 on revenue of $1.1M, with revenue up 300.8% from a year ago. Over its last 8 reports the stock moved an average of 8.8% the session after earnings. Over the last 12 months RNXT insiders bought $131K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is RNXT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RNXT.

Key Stats

Last 12 months
Results
Revenue
$2.8M
Net income
−$13.0M
−469.0% margin
EPS (diluted)
−$0.31
Free cash flow
−$12.2M
−440.4% margin
Valuation
Market cap
$45.5M
48.3M shares
P/E
–
No P/E while losing money
Price to sales
16.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.4M
At Sep 30
Shareholder equity
$9.3M
Shares outstanding
48.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $43K$43KFY2024FY2025: $1.1M$1.1MFY2025

From RNXT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · After the close
Reported EPS
-$0.08
Quarter ended Sep 2026
Year ago EPS
-$0.08
Same quarter last year
Revenue
$1.1M
+300.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.12Dec '24Mar 2025: -$0.08Mar '25Jun 2025: -$0.08Jun '25Sep 2025: -$0.08Sep '25Dec 2025: -$0.08Dec '25Mar 2026: -$0.09Mar '26Jun 2026: -$0.06Jun '26Sep 2026: -$0.08Sep '26Latest -$0.08
Revenue by quarter
Mar 2025: $197,000Mar '25Jun 2025: $422,000Jun '25Sep 2025: $266,000Sep '25Dec 2025: $238,000Dec '25Mar 2026: $563,000Mar '26Jun 2026: $909,000Jun '26Sep 2026: $1.1MSep '26Latest $1.1M
How RNXT moved after its last 8 reports
Average move the session after a report ±8.8%
Nov 5, 2026After the close−5.0%
May 14, 2026After the close−4.1%
Mar 30, 2026After the close−5.6%
Nov 13, 2025After the close−23.0%
Aug 14, 2025After the close−22.9%
May 15, 2025After the close+6.3%
Apr 1, 2025Time not announced−3.0%
Nov 14, 2024Time not announced0.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RNXTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RNXT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RNXT

Technical Analysis

RNXT · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 27% below its 20 day and 43% below its 50 day average. It is 18% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $0.90, and the nearest resistance the swing high (Jul 27) at $0.98.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 15.2%/day
Key levels
$2.5952 week high+175.5%
$1.3550 day average+43.6%
$1.31100 day average+39.4%
$1.2020 day average+27.7%
$1.11200 day average+18.1%
$1.01Pivot R1+7.4%
$0.98Pivot+4.3%
$0.98Swing high (Jul 27)+4.3%
$0.94Last close
$0.90Pivot S1−4.3%
$0.90Swing low (Nov 16)−4.3%
$0.7652 week low−19.1%
Indicators
RSI (14)35.57Weak, oversold below 30Neutral
MACD-0.09Below its signal lineBearish
Stochastic23.5Middle of its rangeNeutral
ADX (14)16.0No clear trend
Williams %R-90.8Oversold below −80, overbought above −20Oversold
CCI (20)-124.3Oversold below −100, overbought above 100Oversold
Rate of change−16.6%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 15.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNXT

What happened before

See how RNXT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RNXT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RNXT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RNXTHow many large options trades hit RNXT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RNXT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲27 buying vs 7 selling
  • ▲Held by funds +6.4 pts
  • ▲Funds holding +12
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4028+42.9%
In funds' top 1000–
Held by funds25.4%19.1%+6.4 pts
New / increased15 / 123 / 8+145.5%
Reduced / sold out3 / 46 / 6−41.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RNXT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RNXT Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$131K10 buys · 3 insiders
Sold$00 sales · 0 insiders
2025-12 bought $37K2026-01 bought $10K2026-05 bought $20K2026-11 bought $46KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Ramtin AgahExecutive Chairman and CMOBuy50,000$0.93$46K
May 19Mark VollCFOBuy25,000$0.79$20K
Jan 21Ramtin AgahChief Medical OfficerBuy10,000$1.00$10K
Dec 31, 2025Ramtin AgahChief Medical OfficerBuy9,795$0.86$8K
Dec 30, 2025Ramtin AgahChief Medical OfficerBuy205$0.83$170
Dec 18, 2025Shaun BagaiCEOBuy5,000$0.90$5K
Every insider buy and sale for RNXT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RNXT insider trades →

From SEC Form 4 filings by RNXT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNXT is in one of them and how their past RNXT trades turned out.

RNXT in the AI portfolios
Loading…

RNXT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RNXT in an article yet. Here's the latest on the wider market.

RNXT in the news

About RenovoRx

RenovoRx is a medical device company based in Mountain View, California. It develops RenovoCath, a proprietary drug delivery device sold as a standalone product, along with other products that combine drugs and devices. Its product candidates are still in clinical trials. Its customers are expected to include physicians, hospitals and other healthcare providers, whose care may be paid for by government programs and private insurers.

Headquarters
Mountain View, CA